FDA Approves Broader Anktiva Use for Bladder Cancer
The FDA approved ImmunityBio’s Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not responded to BCG therapy.
S. ’s (IBRX) drug Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer (NMIBC) that has not responded to a specific therapy called Bacillus Calmette-Guérin (BCG) and has not inv…